Global Healthcare Contract Manufacturing Market Research Report: Forecast to 2023

The global market for healthcare contract manufacturing is estimated to reach USD 250.9 billion by 2023, from USD 129.9 billion in 2016. The market is projected to register a CAGR of 9.86%, during the forecast period of 2017 to 2023.

Reference: 180352
Price: $4,450.00
Tax included

General

Geography Covered
Global
Publisher:
Market Research Future
Publication Date
2018/5/1
Pages
171
Language
  • English
Format
License

Contract manufacturing refers to a manufacturer who contracts with another company to make certain components or products over an equally agreed period. The healthcare contract manufacturing organization serves other companies in the medical devices and pharmaceutical industries to provide comprehensive services from drug development to drug manufacturing.
Pharmaceutical contract manufacturing is a huge sector with a large number of integrated services. Some of the services include Active Pharmaceutical Ingredient (API) manufacturing, Final Dosage Form (FDF) manufacturing, advanced drug delivery products, OTC medicines and nutritional product, packaging, and others. FDF comprises solid dose formulations, semi-solid and liquid dose formulations, and injectables. Similarly, medical device contract manufacturing also includes different services such as outsourcing design, device manufacturing, final goods assembly, and others. Device manufacturing services comprise material process services, electronic manufacturing services, and finished products.
The market for healthcare contract manufacturing is growing at a moderate rate. This growth is mainly attributed to factors such as patent protection expiration of major drugs and medical devices, competition and economics of production and trade to favor CMO, mutual benefits to both contract manufacturer and client, and lean manufacturing and agility. These factors are pushing the growth of the healthcare contract manufacturing market.
On the other hand, certain factors are restraining the growth of the market. These include supply chain complexity and issues of control of third parties, standardization and interoperability issues, and growing cost of noncompliance and counterfeit medicines.
The global market for healthcare contract manufacturing is estimated to reach USD 250.9 billion by 2023, from USD 129.9 billion in 2016. The market is projected to register a CAGR of 9.86%, during the forecast period of 2017 to 2023.
On the basis of type, the market for healthcare contract manufacturing is segmented into sterile contract manufacturing and non-sterile contract manufacturing. By type, the market for non-sterile contract manufacturing accounted for the largest market share in 2016.
On the basis of service type, the market for healthcare contract manufacturing is segmented into pharmaceutical contract manufacturing and medical device contract manufacturing. By service type, the market for pharmaceutical contract manufacturing accounted for the largest market share in 2016.
On the basis of industry, the market is segmented into pharmaceutical, medical device, and biopharmaceutical; where the pharmaceutical industry accounted for the largest market share in 2016.

Key Players
The key players for the healthcare contract manufacturing market are AbbVie, Boehringer Ingelheim, Grifols International, S.A, Lonza AG, Catalant, Aesica Pharmaceuticals, Pharmaceutical Product Development, Pfizer Inc., Baxter Biopharma Solutions, Jubilant Life Sciences Limited, Nipro Corporation, NextPharma Technologies, Patheon, Teva Pharmaceutical Industries, Vetter Pharma International, and others.
Study Objectives
• To provide historical and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries
• To provide insights into factors influencing and affecting the market growth
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global healthcare contract manufacturing market


Target Audience
• Pharmaceutical and Medical Device Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• The major market players in the global healthcare contract manufacturing market are AbbVie, Boehringer Ingelheim, Grifols International, and S.A, Lonza AG
• Abbvie accounted for more than 18% share of the global healthcare contract manufacturing market
• Based on type, non-sterile contract manufacturing commanded the largest market share in 2016 and was valued at USD 95.8 billion in the same year
• Based on service type, the pharmaceutical contract manufacturing segment commanded the largest market share in 2016 and was valued at USD 73.1 billion in the same year
• On the basis of region, the American region is projected to be the fastest growing region, at a CAGR of 10.3% during the forecast period


Regional Analysis
Americas
• North America
o U.S.
o Canada
• South America
Europe
• Western Europe
o Germany
o France
o Italy
o U.K.
o Spain
o Rest of Western Europe
• Eastern Europe
Asia Pacific
o China
o Japan
o India
o Australia
o Republic of Korea
o Rest of Asia Pacific
The Middle East & Africa
• United Arab Emirates
• Saudi Arabia
• Oman
• Kuwait
• Qatar
• Rest of the Middle East & Africa

 

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Patent protection expiration of major drugs and medical devices will boost the market growth
4.2.2 Competition and economics of production and trade to favor CRO
4.2.3 Mutual benefits to both contract manufacturer and client are likely to have a positive impact on healthcare contract manufacturing
4.2.4 Lean manufacturing and agility
4.3 Restraints
4.3.1 Supply chain complexity and issues of control of 3rd parties may hamper the market
4.3.2 Standardization and interoperability issues
4.3.3 Growing cost of noncompliance and counterfeited medicines may hamper the market growth
4.4 Opportunities
4.4.1 Research & development
4.4.2 Personalization & customization
4.5 Challenges
4.5.1 Loss of research and innovation ability
4.5.2 Growth in exposure to natural and human-made threats
5 Market Factor Analysis
5.1 Value/Supply Chain Analysis
5.1.1 Raw Material
5.1.2 Supplier
5.1.3 Manufacturer
5.1.4 Distributor
5.1.5 Customer
5.1.6 Consumer
5.2 Porter’s Five Force Analysis
5.2.1 Threat from a New Entrant
5.2.2 Bargaining Power of Buyer
5.2.3 Bargaining Power of Supplier
5.2.4 Threat from Substitute
5.2.5 Rivalry
5.3 Investment Opportunity Analysis
5.3.1 Market Size (Current & Future), Growth Rate, & Profitability
5.3.2 Investment Risks
5.3.3 Market outlook
6 Global Healthcare Contract Manufacturing Market, By Type
6.1 Overview
6.1.1 Sterile
6.1.2 Non-Sterile
7 Global Healthcare Contract Manufacturing Market, By Service Type
7.1 Overview
7.1.1 Pharmaceutical Contract Manufacturing
7.1.2 Medical Device Contract Manufacturing
8 Global Healthcare Contract Manufacturing Market, By Industry
8.1 Overview
8.1.1 Pharmaceutical Industry
8.1.2 Medical Device Industry
8.1.3 Biopharmaceutical Industry
9 Global Healthcare Contract Manufacturing Market, By Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Competitive Landscape
10.1 Introduction
10.1.1 Company Share Analysis
11 Company Profiles
11.1 Catalant
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offering
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategy
11.2 Boehringer Ingelheim
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offering
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 Lonza AG
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offering
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Grifols International, S.A
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offering
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 AbbVie Inc
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offering
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategy
11.6 Patheon Inc
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offering
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 Vetter Pharma
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offering
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
11.8 Pharmaceutical Product Development
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offering
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Teva Pharmaceutical Industries Limited
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offering
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
11.1 Aesica Pharmaceuticals Ltd
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offering
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategy
11.11 Pfizer Inc.
11.11.1 Company Overview
11.11.2 Financial Overview
11.11.3 Products/Services Offering
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategy
11.12 Baxter Biopharma Solutions
11.12.1 Company Overview
11.12.2 Financial Overview
11.12.3 Products/Services Offering
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategy
11.13 Jubilant Life Sciences Limited
11.13.1 Company Overview
11.13.2 Financial Overview
11.13.3 Products/Services Offering
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.13.6 Key Strategy
11.14 Nipro Corporation
11.14.1 Company Overview
11.14.2 Financial Overview
11.14.3 Products/Services Offering
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.14.6 Key Strategy
11.15 NextPharma Technologies
11.15.1 Company Overview
11.15.2 Financial Overview
11.15.3 Products/Services Offering
11.15.4 Key Developments
11.15.5 SWOT Analysis
11.15.6 Key Strategy
12 Conclusion
12.1 Key Findings
12.1.1 Key Companies to Watch
12.1.2 Prediction of the Healthcare Contract Manufacturing Industry
13 Appendix
13.1 Discussion Blue Print

 

Scroll